Snapshot from Jul 19, 2026 at 14:14 UTC. For live data and tracking: View Live
Events / Regulatory / Capricor Deramiocel FDA Advisory Meeting
Regulatory regulatory review

Capricor Deramiocel FDA Advisory Meeting

Analysis based on 7 articles · First reported Jun 26, 2026 · Last updated Jun 26, 2026

Sentiment
70
Attention
6
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The announcement of the advisory committee meeting for Deramiocel's approval is a positive development for Paragon Therapeutics, potentially increasing investor confidence in the company's ability to bring its lead product to market. Successful approval could lead to significant revenue generation for Paragon Therapeutics and provide a new treatment option for patients with Duchenne muscular dystrophy.

biotechnology pharmaceuticals
Event Summary

Paragon Therapeutics announced that the Cellular, Tissue, and Gene Therapies Advisory Committee of the United States — Food and Drug Administration will hold an advisory committee meeting on July 29, 2026, to review the company's Biologics License Application for Deramiocel. Deramiocel is an investigational cell therapy for Duchenne muscular dystrophy, supported by positive results from Phase 2 and Phase 3 clinical trials. The United States — Food and Drug Administration's PDUFA target action date for the BLA is August 22, 2026. Linda Marban, CEO of Paragon Therapeutics, expressed confidence in the data supporting Deramiocel's skeletal and cardiac benefits.

Entities Involved
priv
Paragon Therapeutics
Paragon Therapeutics announced that the Cellular, Tissue, and Gene Therapies Advisory Committee of the United States — Food and Drug Administration will convene a meeting to discuss its Biologics License Application for Deramiocel, a cell therapy for Duchenne muscular dystrophy. This is a significant step towards potential market approval for their lead product candidate.
Importance 100.0 Sentiment 75.0
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration's Cellular, Tissue, and Gene Therapies Advisory Committee is convening a meeting to review Paragon Therapeutics' Biologics License Application for Deramiocel, which is a critical step in the regulatory approval process for the drug.
Importance 90.0 Sentiment 0.0
per
Linda Marban
Linda Marban, CEO of Paragon Therapeutics, expressed confidence in the evidence supporting Deramiocel and emphasized the company's commitment to bringing the therapy to patients.
Importance 40.0 Sentiment 0.0
govactor
European Union — European Medicines Agency
The European Union — European Medicines Agency has granted Orphan Drug Designation and Advanced Therapy Medicinal Product designation to Deramiocel, indicating its potential importance in Europe, though the current event focuses on U.S. regulatory review.
Importance 20.0 Sentiment 0.0
Relationships
Paragon Therapeutics related ↔ United States — Food and Drug Administration
United States — Food and Drug Administration related ↔ European Union — European Medicines Agency
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.